We are all well aware of the disastrous turn of events in the past 5 years with regard to the rising cost of medications. What were once $4.00 specials at Wal-Mart now cost $50.00 or more.
Changing the schedule of targeted therapies has been shown to improve the response rate in a mouse model of melanoma.
Superficial chemical peels have a relatively low complication rate in patients with darker skin types when performed appropriately, a study published in Journal of the American Academy of Dermatology has found.
A novel picosecond/nanosecond 670 nm wavelength is safe and effective for the treatment of benign pigmented lesions.
Pediatric melanomas are often misdiagnosed by physicians. Adolescents have a more aggressive disease course than children and are treated with adult protocols leading to chronic morbidity.
Oral propranolol may be safe for infants with uncomplicated hemangiomas, but for those with underlying health conditions, it may not always be the treatment of choice.
Observational study shows high heart disease risk in severe and predominantly active atopic eczema.
Efficacy and safety outcomes of clinical trials involving biologic psoriasis drugs overstate these drugs' real-world utility, shows a JAMA Dermatology study.
The TNF alpha inhibitor certolizumab pegol has achieved the highest response rates seen in phase three trials of self-injectable biologics for psoriasis, shows a study published in JAAD.
For some patients with moderate to severe atopic dermatitis, the combination of dupilumab and corticosteroids may be necessary to control flares, a new study shows. Dupilumab is a proven treatment for AD, so where do we go from here? A physician writing in BJD suggests predictive modeling.